OUR PORTFOLIO COMPANIES
As early stage investors, Mission Cure Capital expects above-market returns, but our life science portfolio companies are much more than investment opportunities.
As chronic pancreatitis patients, family members and impact investors, we fuel problem-solvers who share our urgency and measure success by improvements in disease progression and quality of life.
Cedars Sinai
MCC’s investment in this foundational study helped fund a collaboration between the Pandol Laboratory at the Cedars-Sinai Pancreatic Research Program, dedicated to advancing the prevention, early diagnosis and treatment of pancreatic diseases and the Sareen Laboratory, using stem cells (iPSCs) to model diseases and explore tomorrow’s therapeutics.